ライフサイエンスコーパス: graft-versus-host disease

1 x 2(-/-) T cells were protected from severe graft versus host disease.

2 ASIX) was shown to predict death after acute graft-versus-host disease.

3 He experienced mild gut graft-versus-host disease.

4 emic bacterial infection, colitis, and acute graft-versus-host disease.

5 syndrome-like phenotype and aggravated acute graft-versus-host disease.

6 e on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease.

7 t can circumvent central tolerance and limit graft-versus-host disease.

8 ed immune cells can trigger life-threatening graft-versus-host disease.

9 ee-survival, nonrelapse mortality (NRM), and graft-versus-host disease.

10 arsh conditioning, and do not have a risk of graft-versus-host disease.

11 ne inflammatory bowel disease and allogeneic graft-versus-host disease.

12 g regimens, corticosteroids, infections, and graft-versus-host disease.

13 ter accounting for immune reconstitution and graft-versus-host disease.

14 eneic CAR T cells with limited potential for graft-versus-host disease.

15 ty and alloimmunity in models of colitis and graft-versus-host disease.

16 risks related to transplant conditioning and graft-versus-host disease.

17 n dermatitis, cutaneous T-cell lymphoma, and graft-versus-host disease.

18 None had grade III-IV acute or chronic graft-versus-host disease.

19 One patient developed grade I skin graft-versus-host disease.

20 with reduced survival and increased chronic graft-versus-host disease.

21 utoimmune diseases, transplant rejection and graft-versus-host disease.

22 rm of CD43 in multiple T cell subsets during graft-versus-host disease.

23 of the effector cells, but carry the risk of graft-versus-host disease.

24 and tissue manifestations of T-cell-mediated graft-versus-host disease.

25 marrow might promote graft immunogenicity or graft-versus-host disease.

26 myelofibrosis and show promising results in graft-versus-host-disease.

27 ic enterocolitis resembling acute intestinal graft-versus-host-disease.

28 ific antitumour immunity and pathogenesis of graft-versus-host diseases.

29 is associated with morbidity, rejection and graft-versus-host disease(2).

30 accompanied by morbidity and mortality from graft-versus-host disease(5).

31 including hepatitis B virus infection(5-7), graft-versus-host disease(8) and inflammatory bowel dise

32 vention and treatments for acute and chronic graft versus host disease after transplantation.

33 lycosyltransferase gene in T cells mediating graft-versus-host disease after allogeneic bone marrow t

34 iciently suppressed effector T cell-mediated graft-versus-host disease after allogeneic hematopoietic

35 These populations correlate with acute graft-versus-host disease after allogeneic hematopoietic

36 trials to alleviate autoimmune diseases and graft-versus-host disease after hematopoietic stem cell

37 after solid-organ transplantation or prevent graft-versus-host disease after transfer of hematopoieti

38 atients who develop steroid-refractory acute graft-versus-host disease (aGVHD) after allogeneic hemat

39 Acute graft-versus-host disease (aGVHD) continues to be a freq

40 were followed for disease relapse and acute graft-versus-host disease (aGvHD) development post-HSCT.

41 Acute graft-versus-host disease (aGVHD) hinders the efficacy o

42 s have improved survival and decreased acute graft-versus-host disease (aGVHD) in 2 different murine

43 We found that acute graft-versus-host disease (aGVHD) is associated with lym

44 Acute graft-versus-host disease (aGVHD) is the most common com

45 nt of severe and/or steroid-refractory acute graft-versus-host disease (aGVHD) remains a significant

46 The incidence of acute graft-versus-host disease (aGVHD) was compared in patien

47 hematopoietic cell transplantation is acute graft-versus-host disease (aGVHD), a devastating conditi

48 ion viral reactivation, grade II to IV acute graft-versus-host disease (aGvHD), and chronic graft-ver

49 ressor cells (MDSCs) in the setting of acute graft-versus-host disease (aGVHD).

50 is connected to a higher incidence of acute graft-versus-host disease (aGVHD).

51 1.50-5.55; P = 0.002) and grade II-IV acute graft-versus-host disease (aHR, 1.59; 95% CI, 1.06-2.39;

52 ious disease, cancer, regenerative medicine, graft-versus-host disease, allergies, and immunity.

53 tors for its occurrence were the presence of graft versus host disease and the use of alemtuzumab.

54 ll responses with important implications for graft-versus-host disease and graft-versus-leukemia.

55 for diagnosis and evaluation of treatment of graft-versus-host disease and holds promise for other di

56 eneic CAR T cells may cause life-threatening graft-versus-host disease and may be rapidly eliminated

57 clinical symptoms in animal models of acute graft-versus-host disease and multiple sclerosis.

58 amide is associated with low rates of severe graft-versus-host disease and nonrelapse mortality and d

59 d more severe inflammatory bowel disease and graft-versus-host disease and produced higher levels of

60 ecreased after transplant in the presence of graft-versus-host disease and were not replaced, owing t

61 splantation without steroid-refractory acute graft-versus-host disease and without early relapse.

62 at organ or bone-marrow allograft rejection, graft versus host disease, and autoimmune diseases.

63 l for use as models for allotransplantation, graft versus host disease, and regenerative medicine.

64 posttransplant lymphoproliferative disorder, graft-versus-host disease, and enteric infections.

65 Among patients receiving HCT, 27 (40%) had graft-versus-host disease, and most deaths occurred with

66 , invasive mold infection, acute and chronic graft-versus-host disease, and prednisone exposure.

67 cytokine release syndrome, neurotoxicity, or graft-versus-host disease, and there was no increase in

68 ilable because immune complications, such as graft-versus-host disease, are greater without a matched

69 This study also supports chronic graft-versus-host disease as a risk factor for nonmelano

70 stay; intensive care unit admissions; acute graft-versus-host disease; Bearman toxicity score; sinus

71 Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell func

72 Chronic graft-versus-host disease (cGVHD) after allogeneic hemat

73 Chronic graft-versus-host disease (cGVHD) and late acute graft-v

74 injury attributable to experimental chronic graft-versus-host disease (cGVHD) by targeting B-cell ly

75 aft-versus-host disease (aGvHD), and chronic graft-versus-host disease (cGvHD) complicated 49.6%, 35%

76 eclinical and clinical research into chronic graft-versus-host disease (cGVHD) has come to fruition i

77 ssful treatment of older recipients, chronic graft-versus-host disease (cGVHD) has emerged as the maj

78 Chronic graft-versus-host disease (cGVHD) is a leading cause of

79 Chronic graft-versus-host disease (cGVHD) is a major cause of la

80 Chronic graft-versus-host disease (cGVHD) is a major complicatio

81 Chronic graft-versus-host disease (cGVHD) is a notorious complic

82 Chronic graft-versus-host disease (cGVHD) is a serious complicat

83 Chronic graft-versus-host disease (cGVHD) is an autoimmune-like

84 nctions in the pathogenesis of cGVHD.Chronic graft-versus-host disease (cGVHD) is mediated by specifi

85 Chronic graft-versus-host disease (cGVHD) is the main cause of l

86 Although chronic graft-versus-host disease (CGVHD) is the primary nonrela

87 Chronic graft-versus-host disease (cGVHD) represents a double-ed

88 hymocyte globulin-Fresenius) reduces chronic graft-versus-host disease (cGVHD) without compromising s

89 cells contribute to pathogenesis in chronic graft-versus-host disease (cGVHD), a condition manifeste

90 cell transplantation is hampered by chronic graft-versus-host disease (cGVHD), resulting in multiorg

91 y complications in a murine model of chronic graft-versus-host disease (cGVHD).

92 ic autoimmune-like syndrome known as chronic graft-versus-host disease (cGVHD).

93 therapeutic effect in patients with chronic graft-versus-host disease (cGvHD).

94 Chronic graft-versus-host-disease (cGVHD) can cause multiorgan s

95 Patients <50 years old and without chronic graft-versus-host disease, compared with the remaining p

96 Post-transplant severe graft-versus-host disease could be improved, and earlier

97 Chronic pulmonary graft-versus-host disease (cpGVHD) after hematopoietic c

98 patients were assessed for the occurrence of graft-versus-host disease, death, and major functional d

99 r caused by acid reflux, allergic responses, graft-versus-host disease, drugs, or infections, is a co

100 excellent graft function after overcoming a graft-versus-host-disease episode 5 months posttransplan

101 ytopenias) was reported in 4 patients, acute graft-versus-host disease grade 1 in 2, grade 2 in 3, an

102 re safe, and only two occurrences of de novo graft-versus host disease (grade 1) were observed.

103 d loss of diversity correlates with acute GI graft versus host disease (GvHD) and poor outcomes.

104 models, including organ transplantation and graft versus host disease (GVHD) but they have limitatio

105 ls testing prevention strategies for chronic graft versus host disease (GVHD) have measured its cumul

106 Severe pulmonary chronic graft versus host disease (GVHD) is a life-threatening c

107 Chronic graft versus host disease (GVHD) is a major cause of mor

108 ey influence disease processes such as acute graft versus host disease (GVHD), which is the main comp

109 In intestinal transplantation, graft versus host disease (GVHD), while relatively rare,

110 cipients expired by day 40 from severe acute graft versus host disease (GVHD).

111 morbidity and mortality rates, mainly due to graft versus host disease (GvHD).

112 lyl glycine (DMOG) in the pathophysiology of graft versus host disease (GVHD).

113 graftment is development of acute xenogeneic graft- versus-host disease (GVHD) due to human T-cell re

114 A history of graft-versus-host disease (GVHD) ( n = 27) was associate

115 (15%), as were the rates of acute grade 2-4 graft-versus-host disease (GVHD) (21%).

116 ressive therapy required to prevent or treat graft-versus-host disease (GVHD) after allogeneic blood

117 ory T cells (Tregs) can control experimental graft-versus-host disease (GVHD) after allogeneic hemato

118 Graft-versus-host disease (GVHD) after allogeneic stem c

119 mbotic microangiopathy to steroid-refractory graft-versus-host disease (GVHD) after allogeneic stem-c

120 ve, with 8 (26%) deaths related to new-onset graft-versus-host disease (GVHD) after anti-PD-1.

121 s safe and results in low incidence of acute graft-versus-host disease (GVHD) after reduced-intensity

122 th life-threatening complications, including graft-versus-host disease (GVHD) and infections, which a

123 ococcal expansion, which was associated with graft-versus-host disease (GVHD) and mortality.

124 with significant complications, principally graft-versus-host disease (GVHD) and opportunistic infec

125 Graft-versus-host disease (GVHD) and posttransplant immu

126 strategies are used to mitigate the risk of graft-versus-host disease (GvHD) and rejection associate

127 However, graft-versus-host disease (GVHD) and relapse after allo-

128 Secondary outcomes included graft-versus-host disease (GVHD) and relapse.

129 had a reduced incidence and delayed onset of graft-versus-host disease (GVHD) and significantly prolo

130 rted that donor effector T-cell function and graft-versus-host disease (GVHD) are regulated via recip

131 e cumulative incidence of grade 2 to 4 acute graft-versus-host disease (GVHD) at day 100 was 44%, and

132 Human graft-versus-host disease (GVHD) biology beyond 3 months

133 ions contributed to significant reduction in graft-versus-host disease (GVHD) but retained sufficient

134 e colony-stimulating factor (GM-CSF) promote graft-versus-host disease (GVHD) by recruiting donor den

135 Acute graft-versus-host disease (GVHD) can affect the central

136 y T cells (TEM) are less capable of inducing graft-versus-host disease (GVHD) compared with naive T c

137 al targets for the therapy and prevention of graft-versus-host disease (GVHD) following allogeneic he

138 Acute graft-versus-host disease (GVHD) grades 2-4 was more fre

139 A higher incidence of graft-versus-host disease (GVHD) has been observed after

140 occurred in 26 patients (16%), severe acute graft-versus-host disease (GVHD) in 9 (6%), and chronic

141 lls also mediated accelerated onset of acute graft-versus-host disease (GVHD) in a murine model, char

142 Azacitidine (AzaC) mitigates graft-versus-host disease (GvHD) in both murine preclini

143 1 blocking strategy can increase the risk of graft-versus-host disease (GVHD) in murine models.

144 Graft-versus-host disease (GVHD) in the gastrointestinal

145 We have shown that under acute graft-versus-host disease (GVHD) inflammatory conditions

146 Graft-versus-host disease (GvHD) is a common complicatio

147 The development of graft-versus-host disease (GVHD) is a common complicatio

148 Graft-versus-host disease (GVHD) is a complication of al

149 Acute graft-versus-host disease (GVHD) is a frequent complicat

150 Intestinal graft-versus-host disease (GVHD) is a life-threatening c

151 Acute graft-versus-host disease (GVHD) is a life-threatening c

152 Graft-versus-host disease (GVHD) is a major cause of mor

153 Graft-versus-host disease (GVHD) is a major cause of mor

154 Chronic graft-versus-host disease (GVHD) is a major complication

155 Graft-versus-host disease (GvHD) is a major complication

156 Graft-versus-host disease (GVHD) is a major factor contr

157 Graft-versus-host disease (GVHD) is common after allogen

158 The risk of acute graft-versus-host disease (GVHD) is higher after allogen

159 Acute graft-versus-host disease (GVHD) is initially triggered

160 However, graft-versus-host disease (GVHD) is mediated by the same

161 (ICU) remains controversial, especially when graft-versus-host disease (GVHD) is present.

162 Graft-versus-host disease (GVHD) is the major cause of n

163 Graft-versus-host disease (GVHD) is the most serious com

164 Lower gastrointestinal (GI) tract graft-versus-host disease (GVHD) is the predominant caus

165 Yet, our understanding of how PTCy prevents graft-versus-host disease (GVHD) largely has been extrap

166 dence pointing to exacerbation of underlying graft-versus-host disease (GVHD) linked to presence of h

167 However, graft-versus-host disease (GVHD) may develop when donor-

168 oth radiation exposure during transplant and graft-versus-host disease (GVHD) may increase risk of la

169 Gastrointestinal acute graft-versus-host disease (GVHD) occurring after allogen

170 whether the patient has or has not developed graft-versus-host disease (GvHD) or received immunosuppr

171 d the participation of the 5-LO/LTB4 axis in graft-versus-host disease (GVHD) pathogenesis by transpl

172 -based tools may identify a lower-risk acute graft-versus-host disease (GVHD) population amenable to

173 Graft-versus-host disease (GvHD) presents a major cause

174 Despite graft-versus-host disease (GVHD) prophylactic agents, th

175 Sir) vs tacrolimus/methotrexate (Tac/Mtx) as graft-versus-host disease (GVHD) prophylaxis after match

176 ne (CSP) and mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prophylaxis after nonmy

177 While tacrolimus and sirolimus (T/S)-based graft-versus-host disease (GvHD) prophylaxis has been ef

178 f posttransplant cyclophosphamide (PT-Cy) as graft-versus-host disease (GVHD) prophylaxis has revolut

179 ATG) has represented the standard of care in graft-versus-host disease (GVHD) prophylaxis in patients

180 Graft-versus-host disease (GVHD) prophylaxis included ca

181 transplantation from haploidentical donors; graft-versus-host disease (GVHD) prophylaxis included po

182 We used post-transplant cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis to expand d

183 cells as the source of the graft and PTCy as graft-versus-host disease (GvHD) prophylaxis.

184 en and posttransplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis.

185 stem cell transplantation (HSCT) and enteric graft-versus-host disease (GVHD) remain unexplored.

186 splantation continue to improve, but chronic graft-versus-host disease (GVHD) remains a common toxici

187 Despite major advances in recent years, graft-versus-host disease (GVHD) remains a major life-th

188 Acute graft-versus-host disease (GVHD) remains a major limitat

189 Graft-versus-host disease (GVHD) remains a major limitat

190 Acute graft-versus-host disease (GVHD) remains a major obstacl

191 Graft-versus-host disease (GVHD) remains an important ca

192 Treatment of steroid-resistant acute graft-versus-host disease (GVHD) remains an unmet clinic

193 Graft-versus-host disease (GVHD) remains one of the majo

194 s been driven by the premise that persistent graft-versus-host disease (GVHD) results from inadequate

195 tic accuracy of cGVHD and to better classify graft-versus-host disease (GVHD) syndromes but have not

196 er vitamin A levels would reduce the risk of graft-versus-host disease (GVHD) through reduced gastroi

197 s recognize host tissues as foreign, causing graft-versus-host disease (GVHD) which is a main contrib

198 Prevention of graft-versus-host disease (GvHD) without malignant relap

199 Graft-versus-host disease (GVHD), a common complication

200 Alloimmune T cell responses induce graft-versus-host disease (GVHD), a serious complication

201 relapse mortality, and severe (grade 3 or 4) graft-versus-host disease (GVHD), all evaluated through

202 including inflammatory bowel disease (IBD), graft-versus-host disease (GVHD), and cancer.

203 nt in trials of initial treatment of chronic graft-versus-host disease (GVHD), and evidence showing t

204 progression-free survival, acute and chronic graft-versus-host disease (GVHD), and GVHD-free and rela

205 immunologic mismatch can also lead to lethal graft-versus-host disease (GVHD), and immunosuppression

206 cell transplantation (allo-HCT) are relapse, graft-versus-host disease (GVHD), and infection.

207 or cause of morbidity and mortality in acute graft-versus-host disease (GVHD), and pathological damag

208 s associated with a high risk of graft loss, graft-versus-host disease (GvHD), and transplant-related

209 tation is associated with excessive rates of graft-versus-host disease (GVHD), but AZA has been shown

210 (IL-17A) can mediate late immunopathology in graft-versus-host disease (GVHD), however protective rol

211 Graft-versus-host disease (GVHD), however, remains one o

212 entrations are elevated in steroid-resistant graft-versus-host disease (GVHD), implying endothelial h

213 cases at the highest dose in the absence of graft-versus-host disease (GVHD), neurotoxicity, or dose

214 e was no impact of EBV reactivation on acute graft-versus-host disease (GVHD), nonrelapse mortality,

215 y as observed in a mouse model of intestinal graft-versus-host disease (GVHD), providing a roadmap fo

216 allogeneic immune-mediated gastrointestinal graft-versus-host disease (GVHD), the principal toxicity

217 the pathogenesis of intestinal mucositis and graft-versus-host disease (GVHD), these cytokines are co

218 has been shown to exacerbate the severity of graft-versus-host disease (GVHD), whereas costimulation

219 tic cell transplantation (HCT) is limited by graft-versus-host disease (GVHD), which is the main post

220 nal microbiome-dependent metabolite, worsens graft-versus-host disease (GVHD).

221 gressive immunosuppression to better control graft-versus-host disease (GvHD).

222 he toxicity of preconditioning therapies and graft-versus-host disease (GVHD).

223 vaccine or a fourth PCV dose in the case of graft-versus-host disease (GvHD).

224 sory nerve damage in a mouse model of ocular graft-versus-host disease (GVHD).

225 amide expanded the donor pool while limiting graft-versus-host disease (GVHD).

226 les are associated with an increased risk of graft-versus-host disease (GVHD).

227 host normal tissues through the often fatal graft-versus-host disease (GVHD).

228 fferentiate between relapse and the onset of graft-versus-host disease (GVHD).

229 ed allo-immune responses will lead to lethal graft-versus-host disease (GVHD).

230 ith increased mortality and gastrointestinal graft-versus-host disease (GVHD).

231 stem cell transplantation resulting in acute graft-versus-host disease (GVHD).

232 kemia (GVL) reactivity, with a lower risk of graft-versus-host disease (GVHD).

233 ved between groups in the incidence of acute graft-versus-host disease (GVHD).

234 dels of inflammatory bowel disease and acute graft-versus-host disease (GVHD).

235 contributes to pathology in animal models of graft-versus-host disease (GVHD).

236 it Itpkb signaling as a means of controlling graft-versus-host disease (GVHD).

237 papular rash on the skin was consistent with graft-versus-host disease (GVHD).

238 (PSV23) or a fourth PCV dose in the case of graft-versus-host disease (GvHD).

239 lications, predominantly infection and acute graft-versus-host disease (GVHD).

240 ological malignancies but remains limited by graft-versus-host disease (GVHD).

241 +/CD19+ graft depletion effectively prevents graft-versus-host disease (GVHD).

242 was used for preventing graft rejection and graft-versus-host disease (GVHD); no patient received an

243 Acute graft-versus-host-disease (GVHD) after non-myeloablative

244 1 therapy reported substantial toxicity from graft-versus-host-disease (GVHD).

245 No treatment-related death or graft-versus-host disease had been reported; 15 of the 1

246 The CI of acute graft-versus-host disease II to IV was 32.3% after RIC a

247 n trials have shown benefits in treatment of graft versus host disease in matched or mismatched stem

248 3, and grade 3-4 in 1, and moderate chronic graft-versus-host disease in 1 patient.

249 reg cells in association with clinical acute graft-versus-host disease in allogeneic hematopoietic ce

250 cells are central mediators of rejection and graft-versus-host disease in both solid organ and hemato

251 munization with OVA and induction of chronic graft-versus-host disease in female ERalpha-knockout mic

252 enhancing T cell regeneration and mitigating graft-versus-host disease in HSCT.

253 ity was observed, except for a grade II skin graft-versus-host disease in the patient treated for hem

254 in eight patients (38%), grade 1 acute skin graft-versus-host disease in two patients (10%), and gra

255 interval, 1.84-31.7), controlling for acute graft-versus-host disease, in 109 patients with Philadel

256 t-related mortality (TRM), acute and chronic graft-versus-host disease incidence and severity, time t

257 ut toxic conditioning and with a low risk of graft versus host disease is a visionary but realistic g

258 s-host disease prophylaxis and in refractory graft-versus-host disease is associated with improved su

259 t-versus-host disease (cGVHD) and late acute graft-versus-host disease (L-aGVHD) are understudied com

260 t in vivo alloresponses using a severe acute graft versus host disease model.

261 ic stem cell transplantation, with grade 3-4 graft-versus-host disease observed in five (26%).

262 rrow-liver-thymus (BLT) mouse model prone to graft-versus-host disease occurred only following revers

263 s inflammatory episodes, or acute or chronic graft-versus-host disease, occurred in any patient.

264 CT recipients without increasing the risk of graft-versus-host disease or disease relapse.

265 lymphoproliferative disorder (P = 0.09) and graft versus host disease (P = 0.002).

266 lymphocytic leukemia (P = 0.02), and chronic graft-versus-host disease (P = 0.0002).

267 -versus-host disease (P = 0.03), and chronic graft-versus-host disease (P = 0.003).

268 (P = 0.004, hazard ratio = 8.2) and chronic graft-versus-host disease (P = 0.010, hazard ratio = 5.3

269 ced-intensity conditioning (P = 0.02), acute graft-versus-host disease (P = 0.03), and chronic graft-

270 secondary Sjogren's disease (P = 0.08), and graft-versus-host disease (P = 0.04).

271 d HCT, myeloablative conditioning, and acute graft-versus-host disease (P values < .01).

272 tion, cyclophosphamide, and fludarabine) and graft-versus-host disease prophylaxis (calcineurin inhib

273 the sequence of therapeutic classes used in graft-versus-host disease prophylaxis and in refractory

274 th cyclophosphamide (CY; days -2 and +2) for graft-versus-host disease prophylaxis, and 1.5 x 10(7) h

275 h adult unrelated donors, using conventional graft-versus-host disease prophylaxis.

276 ace/ethnicity, malignant disease, graft, and graft-versus-host-disease prophylaxis), ST2 remained ass

277 Grade II to IV acute graft-versus-host disease related to steroid treatment s

278 Acute and chronic graft-versus-host disease remain important complications

279 donor CD8(+) T cells (T(TCR-C4)) to minimize graft-versus-host disease risk and enhance transferred T

280 get tissue damage in a unique in vitro human graft-versus-host disease skin explant model.

281 seases(1), including steroid-resistant acute graft versus host disease (SR-aGvHD)(2).

282 teroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) poses one of the mo

283 Therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains suboptimal.

284 nt among patients who developed severe acute graft-versus-host disease, suggesting that short telomer

285 tumor rejection without inducing xenogeneic graft-versus-host disease, thus resulting in significant

286 d can lead to inflammatory disorders such as graft-versus-host disease, transplant rejection and auto

287 reinduction or consolidation chemotherapy or graft versus host disease treatment in hematopoietic ste

288 ose receiving systemic immunosuppression for graft-versus-host disease treatment.

289 vation including age >/=50 years and chronic graft-versus-host disease; treatment strategies based on

290 t conditions such as hepatitis C vasculitis, graft-versus-host disease, type 1 diabetes, and systemic

291 age at transplantation; steroid use, chronic graft-versus-host disease; use of fludarabine, melphalan

292 umulative incidence of grade III to IV acute graft-versus-host disease was 36% by D+100.

293 The CI of chronic graft-versus-host disease was 61.6% after RIC and 64.7%

294 In multivariate analysis, chronic graft-versus-host disease was a significant risk factor

295 Worsening graft-versus-host disease was not identified among Allo

296 hymocyte antiglobulin, and acute and chronic graft versus host disease were significantly associated

297 ; P < .001) and chronic (HR, 0.35; P < .001) graft-versus-host disease were lower with transplantatio

298 cyte count <300 cells/uL at D +30, and acute graft-versus-host disease were predictors of ADV viremia

299 ations were predictors for the occurrence of graft-versus-host disease, whereas CMV and BK virus reac

300 oth patients were alive, without evidence of graft-versus-host disease, with major infection at 1 yea